{"id":"NCT00471146","sponsor":"Pfizer","briefTitle":"Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.","officialTitle":"A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2009-01","completion":"2010-11","firstPosted":"2007-05-09","resultsPosted":"2012-07-16","lastUpdate":"2012-07-16"},"enrollment":630,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Pancreatic Ductal"],"interventions":[{"type":"DRUG","name":"AG-013736","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Baseline until death or at least 1 year after the randomization of last participant","effectByArm":[{"arm":"Axitinib + Gemcitabine","deltaMin":36.9,"sd":null},{"arm":"Placebo + Gemcitabine","deltaMin":35.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5436"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":204,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","France","Germany","Hong Kong","Hungary","India","Ireland","Italy","Japan","Netherlands","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["21306953"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061028&StudyName=Study%20Of%20Gemcitabine%20Plus%20AG-013736%20Versus%20Gemcitabine%20For%20Advanced%20Pancreatic%20Cancer."]},"adverseEventsSummary":{"seriousAny":{"events":108,"n":304},"commonTop":["Nausea","Fatigue","Decreased appetite","Vomiting","Constipation"]}}